Expression of aminopeptidase N (APN) on peripheral blood mononuclear cells′ surface as a marker of these cells′ transendothelial migration properties in the course of multiple sclerosis

Abstract

CD13 Ag and CD11a, CD11b, CD18 molecule expression on peripheral blood mononuclear cells (PBMC) were studied as these cells' adherent or transendothelial migration properties in three different multiple sclerosis (MS) patients groups (total 38): with clinically active MS (acute exacerbation of MS and primary chronic progressive MS (CP-MS)) and with MS remission. The control group consisted of patients, suffering from other non-inflammatory neurological diseases (OND). The results of our study suggest that CD11a/CD18 molecules expression on PB lymphocytes, although higher on these cells' surface in the course of MS as compared to OND, does not differentiate clinical forms of MS. CD11a molecule expression on monocytes did not differ significantly in all tested MS patient groups in comparison to OND. Although the expression of CD11b/CD18 molecules on monocytes' surface shows their activation in the course of MS, it does not differentiate them either. However, CD13 Ag of APN expression on PBMC surface may be an immunological marker of MS clinical form. CD13 Ag expression may also be a sensitive marker of these cells' transendothelial migration properties.

Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects

“…30,31 Overexpression of APN/CD13 in T lymphocytes or neutrophils occurs in several inflammatory diseases (chronic pain, various forms of joint effusions, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis, pulmonary sarcoidosis). [32][33][34][35][36][37][38][39] APN/CD13 may be therefore considered as a useful clinical marker. Whether this protease critically contributes to the pathological behavior remains however unknown.…”

CD13/aminopeptidase N is a negative regulator of mast cell activation

“…Moreover, Wulfänger et al (36) have reported on severely reduced CD13 levels on melanoma cells due to DNA methylation of the myeloid CD13 promoter. In contrast, overexpressiono fC D 1 3i nn e u t r o p h i l so r T lymphocytes can occur in several inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis) (37,38). Though none of these reports was on MCs, they clearly demonstrate that multiple ways of regulation of CD13 expression indeed do exist.…”

“…In contrast, overexpression of CD13 in neutrophils or T lymphocytes can occur in several inflammatory diseases ( e.g. , rheumatoid arthritis, multiple sclerosis) (37, 38). Though none of these reports was on MCs, they clearly demonstrate that multiple ways of regulation of CD13 expression indeed do exist.…”

Aminopeptidase N (EC 3.4.11.2) inhibitors (2006 – 2010): a patent review

“…APN was also reported to be the receptor of cell surface NGR motif [69]. Otherwise, as CD13 [70], APN with different epitopes played various important roles in the modulation of immune microenvironment [71] and immune-related diseases [72]. However, it is difficult to identify the compounds interacting with the function not relevant with peptide-hydrolysis of APN in the enzyme activity assay, and such compounds have not been reported in the patents during the past 5 years either.…”